Edwards Lifesciences Corporation Stock News

Edwards Lifesciences reported fourth-quarter profit on Tuesday that beat Wall Street estimates, helped by strong demand for the company's artificial heart valves and other devices.

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW). But which of these two companies is the best option for thos

Beyond analysts' top -and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, a

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integer (ITGR) and Edwards Lifesciences (EW). But which of these two stocks presents investors with

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

Edwards Lifesciences is down 3.10% over the last year but I am bullish due to its optimistic outlook and growth initiatives. The company is committed to its shareholders through EPS growth and share b

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW). But which of these two stocks offers value investors a bette

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Bernard Zovighian, c

On December 7, 2024, Edwards Lifesciences EW Corporation (NYSE: EW, $76.90, Market Capitalization: $46.6 billion) in its annual investor call announced its plans to spin-off its Critical Care unit int

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW). But which of these two companies is the best option for thos

Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.